Ertumaxomab

Ertumaxomab (trade name Rexomun) is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer.

Ertumaxomab
Monoclonal antibody
TypeTrifunctional antibody
SourceRat/mouse hybrid
TargetHER2/neu, CD3
Clinical data
Trade namesRexomun
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
 NY (what is this?)  (verify)

It is a trifunctional antibody which works by linking T-lymphocytes and macrophages to the cancer cells.[1]

Phase II clinical trial evaluating the treatment of breast cancer was terminated due to change in Fresenius' development plans.[2] (So they could concentrate on their other product catumaxomab (trade name Removab).[3]:35)

References
  1. Fresenius
  2. ClinicalTrials.gov: Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy
  3. 2009 Consolidated Financial Statements and Management Report of Fresenius SE



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.